Fingerpaint Group has a mind to draw biopharma companies a clearer picture of their market access options—and now it has MYND to help it do so. By acquiring MYND Group, Fingerpaint has continued its takeover spree and added to the capabilities of its recently rebranded market access group.

Healthcare marketing agency Fingerpaint moved into market access early in 2020 with the acquisition of 1798, a California-based developer of market access and commercialization support programs. Late last year, Fingerpaint dropped the 1798 name. Rebranded as Fingerpaint Market Access, the unit, which had been involved in 30 launches in the previous three years, pitched itself as an end-to-end consultancy.

Now, Fingerpaint has added to its market access capabilities. MYND is a Pennsylvania-based provider of a range of market access services, spanning from market research through to the training of sales teams. The services overlap with Fingerpaint’s existing capabilities.

In a statement, Bill McEllen, global president at Fingerpaint, highlighted “the growing vaccine category” as an area in which MYND has “extensive market access strategy, research and launch experience.” The vaccine category is heating up, with COVID-19 going commercial, mRNA shots trying to disrupt influenza incumbents, the birth of the respiratory syncytial virus vaccine market and more.   

Reference:

https://www.fiercepharma.com/marketing/fingerprint-spying-growing-vaccine-market-buys-mynd-expand-market-access-capabilities